Background
==========

Worldwide, congestive heart failure (CHF) remains a leading cause of morbidity and mortality \[[@b1-medscimonit-26-e922129]--[@b4-medscimonit-26-e922129]\]. Several diagnostic and prognostic markers are used in patients with CHF, including serum N-terminal pro-B-type natriuretic peptide (NT-proBNP), which are used to guide clinical management \[[@b4-medscimonit-26-e922129]--[@b7-medscimonit-26-e922129]\].

Transthoracic echocardiography (TTE) is commonly used to evaluate cardiac function and cardiac structure in clinical practice \[[@b8-medscimonit-26-e922129]\]. The left ventricular ejection fraction (LVEF) can be measured by TTE and is an important parameter that reflects left ventricular systolic function \[[@b8-medscimonit-26-e922129]\]. Previously published studies have shown that increased left ventricular volume (LVV) is significantly associated with worse prognosis in patients with heart failure and reduced ejection fraction (HFrEF) \[[@b9-medscimonit-26-e922129]--[@b11-medscimonit-26-e922129]\]. Post previously published studies have investigated two-dimensional transthoracic echocardiography (2D-TTE) to evaluate LVEF and LVV, but these values may be underestimated, especially when the left ventricle does not conform to a normal geometric shape \[[@b8-medscimonit-26-e922129]\]. Recently, the use of three-dimensional transthoracic echocardiography (3D-TTE) to assess cardiac function and structure has gradually increased, which is largely attributed to its advantages in the imaging quality and accuracy for the estimation of LVEF and LVV estimation \[[@b12-medscimonit-26-e922129]--[@b14-medscimonit-26-e922129]\]. However, little is known about the differences between 2D-TTE and 3D-TTE predicting prognosis in patients with HFrEF, which may guide clinical therapy.

Therefore, this study aimed to compare the predictive role of two-dimensional transthoracic echocardiography (2D-TTE) and three-dimensional transthoracic echocardiography (3D-TTE) on in-hospital all-cause mortality in patients with HFrEF due to ischemic heart disease (IHD).

Material and Methods
====================

Patients studied
----------------

The protocol of this retrospective study was approved by the local Research Ethics Committee, which did not require informed patient consent. Patients were diagnosed with heart failure on hospital admission between January 2018 to July 2019. The study included patients with ischemic heart disease (IHD) who had a left ventricular ejection fraction (LVEF) \<40% on admission when measured by two-dimensional transthoracic echocardiography (2D-TTE) and three-dimensional transthoracic echocardiography (3D-TTE). The definition of heart failure due to IHD was based on a prior documented history of myocardial infarction (MI), or coronary heart disease, prior percutaneous coronary intervention (PCI), or coronary artery bypass graft (CABG) surgery. The flowchart of the study design is shown in [Figure 1](#f1-medscimonit-26-e922129){ref-type="fig"}.

Clinical and laboratory data
----------------------------

Baseline data were extracted from the patient electronic health records by two independent investigators. The clinical data at admission included the vital signs of systolic and diastolic blood pressure (SBP/DBP) and the heart rate (HR). Patient demographic data included age and gender. Risk factors included smoking status, obesity, hypertension, diabetes mellitus, and dyslipidemia. Comorbidities documented included ischemic stroke, chronic kidney disease (CKD), atrial fibrillation, and previous MI, PCI, and CABG. Specifically, obesity was defined as a body mass index (BMI) ≥30 kg/m^2^. The laboratory results recorded on hospital admission included serum hemoglobin (Hb) levels, fasting blood glucose (FBG), total cholesterol (TC), high-sensitivity cardiac troponin I (hs-cTnI), and N-terminal pro-B-type natriuretic peptide (NT-proBNP). The creatinine level was used to calculate the estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) formula \[[@b15-medscimonit-26-e922129]\], and CKD was defined as an eGFR \<60 ml/min/1.73 m^2^. Medications used on hospital admission and during hospitalization were also recorded.

The 2D-TTE and 3D-TTE examinations
----------------------------------

Certified and experienced clinicians performed the 2D-TTE and 3D-TTE, and all measurements were conducted in accordance with the current guideline recommendations \[[@b8-medscimonit-26-e922129]\]. The 2D-TTE was performed with the patient placed in the left lateral decubitus position, and the left ventricular volume (LVV) was obtained from the apical views. Data of the LV end-diastolic volume (LVEDV) were obtained from the frame after the mitral valve was closed, The LV end-systolic volume (LVESV) was obtained on the image with the smallest LV cavity. The left ventricular ejection fraction (LVEF) was calculated using the Sonos 7500 software for the ie33 system (Philips Medical Systems, Andover, MA, USA).

The 3D-TTE was performed with a similar patient procedure to the 2D-TTE. The volume data were shown in three different cross-sections, and images for the LVEDV and LVESV measured were identified by the same method as for 2D-TTE. Measurements were obtained with semi-automated LV border detection based on fiducial marks on the annulus and apex. Both 2D-TTE and 3D-TTE volumes were indexed to body surface area, as appropriate.

Assessment of the clinical endpoint of all-cause mortality
----------------------------------------------------------

The clinical endpoint was defined as all-cause mortality during hospitalization. This endpoint and mortality were evaluated by an independent cardiologist who reviewed the clinical records.

Statistical analysis
--------------------

Continuous variables were presented as the mean±standard deviation (SD), and categorical variables were presented as the number and percentage. Student's t-test was used to compare continuous variables and the chi-squared (χ^2^) test was used to compare categorical variables. Univariate and multivariate regression analysis were used to evaluate the factors associated with the clinical endpoint. The factor with a P-value \<0.1 in the univariate regression model was entered into the multivariate regression model. The LVEF and LVV measured by 2D-TTE and 3D-TTE were entered into the models separately. The significant factors identified in the multivariate regression model were used to generate the risk prediction model, and parameters derived from 2D-TTE and 3D-TTE were entered into these models separately. Models discrimination were compared by the concordance statistic (C-index). The odds ratio (OR) and the 95% confidence interval (CI) were calculated. All statistical tests were two-sided and were considered to be statistically significant with a P-value \<0.05. Statistical analysis was performed using SPSS version 21.0 software (IBM Corp., Armonk, NY, USA).

Results
=======

Comparison of the demographic and clinical characteristics of the patients in the survival group and the mortality group
------------------------------------------------------------------------------------------------------------------------

The study included 224 patients with heart failure with reduced ejection fraction (HFrEF), or systolic heart failure, due to ischemic heart disease (IHD) who had a left ventricular ejection fraction (LVEF) \<40% on admission when measured by two-dimensional transthoracic echocardiography (2D-TTE) and three-dimensional transthoracic echocardiography (3D-TTE). Patients were classified as the survival group (n=142) and the mortality group (n=82). Between-group differences were evaluated. As shown in [Table 1](#t1-medscimonit-26-e922129){ref-type="table"}, compared with patients in the survival group, patients in the mortality group were older (67.3±15.5 *vs.* 62.6±14.6 years) and more likely to be women (48.8% *vs.* 38.7%). Systolic blood pressure (121±16 *vs.* 109±12 mmHg) and heart rate (89±15 *vs.* 82±12 mmHg) on hospital admission were also significantly higher in the mortality group compared with patients in the mortality group. Patients in the mortality group were also more likely to have diabetes mellitus (51.2% *vs.* 32.4%), chronic kidney disease (48.8% *vs.* 32.4%), and lower eGFR (61.9±10.5 *vs.* 68.6±12.7 ml/min/1.73 m^2^). Serum levels of high-sensitivity cardiac troponin I (hs-cTnI) (45±16 *vs.* 32±12 ng/L) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) (1224±106 *vs.* 946±88 pg/mL) on hospital admission were also significantly higher in mortality versus survival patients. Also, compared with the patients in the survival group, patients in the mortality group had a higher functional class 9Class III/IV) in the New York Heart Association (NYHA) classification of heart failure (46.3% *vs.* 39.4%).

Comparison of the medications used on admission and during hospitalization of the patients in the survival group and the mortality group
----------------------------------------------------------------------------------------------------------------------------------------

As shown in [Table 2](#t2-medscimonit-26-e922129){ref-type="table"}, compared with patients in the survival group, patients in the mortality group were less likely to be treated with beta-blockers (54.9% *vs.* 66.9%) and more likely to receive digoxin therapy on hospital admission (43.9% *vs.* 30.3%). During hospitalization, all patients received intravenous furosemide, and the use of beta-blockers were reduced in both groups. The use of an intravenous inotrope (85.4% *vs.* 76.1%) and an intravenous vasodilator (70.7% *vs.* 61.3%) was significantly increased in the mortality group compared with the survival group.

Comparisons of 2D-TTE and 3D-TTE parameters
-------------------------------------------

[Table 3](#t3-medscimonit-26-e922129){ref-type="table"} shows that from 2D-TTE, there were only differences in the left ventricular end-diastolic volume (LVEDV) and the LVEDV index between patients in the survival group and patients in the mortality group. Measurements by 3D-TTE showed significant differences in LVEF (32±7% *vs.* 29±8%), LVEDV (91.7±20.8 *vs.* 96.5±22.4 ml), and the LVEDV index (45.8±10.4 *vs.* 49.1±12.6 ml/m^2^), the LVESV (45.9±13.3 *vs.* 49.6±14.0 ml) and LVESV index (23.6±6.3 *vs.* 26.0±7.9 ml/m^2^) were observed between patients in the survival group and patients in the mortality group.

Factors associated with all-cause mortality during hospitalization
------------------------------------------------------------------

[Table 4](#t4-medscimonit-26-e922129){ref-type="table"} shows that in the univariate regression model that included the 2D-TTE parameters, increased age, female gender, increased systolic blood pressure (SBP), smoking, hypertension, diabetes mellitus, a history of myocardial infarction (MI) and coronary artery bypass graft (CABG) surgery, the use of intravenous inotropes, increased levels of high-sensitivity cardiac troponin I (hs-cTnI) and NT-proBNP, and increased LVEDV index were associated with an increased risk of all-cause mortality. In contrast, an increased eGFR and LVEF were associated with a reduced risk of all-cause mortality. In the multivariate regression model, only age, diabetes mellitus, a previous MI, the use of intravenous inotropes, the levels of NT-proBNP, and the LVEF were significantly associated with all-cause mortality. The univariate regression model using the 3D-TTE parameters showed similar associations between factors and all-cause mortality. In the multivariate regression model, age, diabetes mellitus, prior MI, intravenous inotrope use, NT-proBNP, LVEF, and the LVEDV index remained significantly associated with all-cause mortality.

Comparisons between 2D-TTE and 3D-TTE parameters for the risk of in-hospital all-cause mortality
------------------------------------------------------------------------------------------------

Significant factors identified in the multivariate regression model were used to generate the predictive models for the risk of in-hospital all-cause mortality. [Table 5](#t5-medscimonit-26-e922129){ref-type="table"} shows the data from the models using the 2D-TTE parameters. The concordance statistic (C-index) was increased significantly after adding LVEF into model 1 (from 0.72 to 0.77). In the model with 3D-TTE parameters, the C-index increased significantly after including the LVEF (from 0.72 to 0.80) and the LVEDV index (from 0.80 to 0.76) into model 1.

Discussion
==========

In this study, a comparison of the predictive role of two-dimensional transthoracic echocardiography (2D-TTE) and three-dimensional transthoracic echocardiography (3D-TTE) on in-hospital all-cause mortality in patients with heart failure and reduced ejection fraction (HFrEF) due to ischemic heart disease (IHD) showed two main findings. The left ventricular ejection fraction (LVEF), which was assessed by either 2D-TTE or 3D-TTE, was independently associated with in-hospital all-cause mortality in HFrEF patients with IHD, but only the left ventricular end-diastolic volume (LVEDV) index measured by 3D-TTE was independently associated with in-hospital all-cause mortality. Secondly, the LVEF measured by 3D-TTE was superior to 2D-TTE in predicting in-hospital all-cause mortality according to the change in the concordance statistic (C-index). Also, the LVEDV index measured by 3D-TTE improved the predictive model generated by traditional clinical risk factors. These findings of this preliminary study may have clinical implications for the prediction of in-hospital all-cause mortality and in guiding clinical therapy for patients with HFrEF.

According to the reports of epidemiologic studies, heart failure causes substantial morbidity and mortality around the world, including China \[[@b16-medscimonit-26-e922129]--[@b19-medscimonit-26-e922129]\]. The 5-year mortality rate is up to 50% after the onset of clinical symptoms \[[@b20-medscimonit-26-e922129]--[@b22-medscimonit-26-e922129]\]. A variety of clinical factors have been identified associated with worse outcomes in HFrEF patients. For example, combing cohorts from HF-ACTION trial and the ASIAN-HF registry, Cooper et al. reported that after adjusted for other covariates, diabetes mellitus was significantly associated with the composite 1-year overall mortality and hospitalization for heart failure, with a hazard ratio (HR) of 1.37 (95% CI, 1.19--1.57) \[[@b23-medscimonit-26-e922129]\]. Consistent to this report, our current study also showed that the presence of diabetes mellitus was associated with a 17--25% increased risk of in-hospital mortality. These findings suggest that well-controlled diabetes may improve the prognosis of patients with heart failure. Recent studies have shown that sodium-glucose cotransporter-2 (SGLT-2) inhibitor improved prognosis in diabetic patients with coexistent heart failure \[[@b24-medscimonit-26-e922129]--[@b27-medscimonit-26-e922129]\]. Also, N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a sensitive and specific biomarker for heart failure, and previous studies have shown that change in serum NT-proBNP level can be used to predict progress and prognosis of HFrEF patients \[[@b6-medscimonit-26-e922129],[@b7-medscimonit-26-e922129],[@b27-medscimonit-26-e922129]\]. In the present study, an increased serum NT-proBNP level on hospital admission was associated with a 21--28% increased risk of in-hospital mortality.

LVEF is another useful marker to predict the outcome in patients with HFrEF. Previous studies have shown that reduced LVEF was independently associated with increased mortality and re-hospitalization for heart failure \[[@b28-medscimonit-26-e922129]--[@b30-medscimonit-26-e922129]\]. However, most previously published studies have used 2D-TTE to assess LVEF. To our knowledge, few previous studies have evaluated the prognostic value of 3D-TTE for the patients with HFrEF. The present study was an extension of previous studies reported by our group \[[@b31-medscimonit-26-e922129]--[@b33-medscimonit-26-e922129]\]. Among the parameters from 2D-TTE, only LVEF was independently associated with in-hospital mortality, after adjusting for covariates. However, both the LVEF and the LVEDV index derived from 3D-TTE were independently associated with in-hospital mortality, suggesting that the parameters from 3D-TTE might provide more data on assessing mortality risk in patients with HFrEF. In the risk-predictive model, after adding parameters into clinical factors, only LVEF from 2D-TTE increased the concordance statistic (C-index) while both the LVEF and the LVEDV index from 3D-TTE significantly increased the C-index. These findings suggested that the LVEF and the LVEDV derived from 3D-TTE were superior to those derived from 2D-TTE to predict in-hospital mortality in patients with HFrEF.

The clinical implications of current findings were in HFrEF patients, 3D-TTE might be better than 2D-TTE in evaluating the severity and in-hospital prognosis of HFrEF patients, and physicians might use parameters from 3D-TTE to better guide the therapy. Future research directions should focus on whether 3D-TTE can improve predictive value in a larger and prospective cohort of HFrEF patients; and whether 3D-TTE guided therapy can improve clinical outcomes in patients with HFrEF.

This study had several limitations. This study was retrospective, and no causal relationship can be established from the findings. Second, only HFrEF patients with IHD were enrolled in the study, and whether these findings can be extrapolated to patients with heart failure and preserved ejection fraction (HFpEF) or HFrEF patients with a non-ischemic etiology remain unknown. Finally, only the in-hospital all-cause mortality was evaluated, and whether these models can be used to predict long-term mortality and re-hospitalization for heart failure require further study.

Conclusions
===========

This study aimed to compare the predictive and prognostic role of two-dimensional transthoracic echocardiography (2D-TTE) and three-dimensional transthoracic echocardiography (3D-TTE) on in-hospital all-cause mortality in patients with heart failure with reduced ejection fraction (HFrEF), or systolic heart failure, due to ischemic heart disease (IHD). In patients with HFrEF due to IHD, 3D-TTE was a better predictor than 2D-TTE of in-hospital all-cause mortality. Further prospective and multicenter studies are needed to validate these preliminary findings.
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![The flowchart of the study to compare the predictive role of two-dimensional transthoracic echocardiography (2D-TTE) and three-dimensional transthoracic echocardiography (3D-TTE) on in-hospital all-cause mortality in patients with heart failure and reduced ejection fraction (HFrEF) due to ischemic heart disease (IHD).](medscimonit-26-e922129-g001){#f1-medscimonit-26-e922129}

###### 

The demographic and clinical characteristics of the survival group and the mortality group of patients with heart failure with reduced ejection fraction (HFrEF) due to ischemic heart disease (IHD).

  Variable                           Survival group (n=142)   Mortality group (n=82)
  ---------------------------------- ------------------------ ------------------------------------------------------------------
  Age (years)                        62.6±14.6                67.3±15.5[\*](#tfn2-medscimonit-26-e922129){ref-type="table-fn"}
  Female patient, n (%)              55 (38.7)                40 (48.8)[\*](#tfn2-medscimonit-26-e922129){ref-type="table-fn"}
  Systolic blood pressure, (mmHg)    109±12                   121±16[\*](#tfn2-medscimonit-26-e922129){ref-type="table-fn"}
  Diastolic blood pressure, (mmHg)   74±10                    72±8
  Heart rate, (beat per minute)      82±12                    89±15[\*](#tfn2-medscimonit-26-e922129){ref-type="table-fn"}
  Current smoker, n (%)              62 (43.7)                38 (46.3)
  Obese, n (%)                       38 (26.8)                20 (24.4)
  Hypertension, n (%)                102 (71.8)               60 (73.2)
  Dyslipidemia, n (%)                74 (52.1)                44 (53.7)
  Diabetes mellitus, n (%)           46 (32.4)                42 (51.2)[\*](#tfn2-medscimonit-26-e922129){ref-type="table-fn"}
  Ischemic stroke, n (%)             31 (21.8)                20 (24.4)
  Chronic kidney disease, n (%)      46 (32.4)                40 (48.8)[\*](#tfn2-medscimonit-26-e922129){ref-type="table-fn"}
  Atrial fibrillation, n (%)         41 (28.9)                23 (28)
  Myocardial infarction, n (%)       125 (88)                 72 (87.8)
  Previous PCI, n (%)                96 (67.6)                55 (67.1)
  Previous CABG, n (%)               34 (23.9)                18 (22)
  Hemoglobin (g/dL)                  13.6±2.2                 13.3±2.4
  Total cholesterol (mmol/L)         5.1±1.0                  5.0±1.1
  Fasting blood glucose (mmol/L)     6.0±0.8                  6.2±1.0
  hs-cTnI (ng/L)                     32±12                    45±16[\*](#tfn2-medscimonit-26-e922129){ref-type="table-fn"}
  NT-proBNP (pg/mL)                  946±88                   1224±106[\*](#tfn2-medscimonit-26-e922129){ref-type="table-fn"}
  eGFR (ml/min/1.73 m^2^)            68.6±12.7                61.9±10.5[\*](#tfn2-medscimonit-26-e922129){ref-type="table-fn"}
  NYHA class I/II                    86 (60.6)                44 (53.7)[\*](#tfn2-medscimonit-26-e922129){ref-type="table-fn"}
  NYHA class III/IV                  56 (39.4)                38 (46.3)[\*](#tfn2-medscimonit-26-e922129){ref-type="table-fn"}

PCI -- percutaneous coronary intervention; CABG -- coronary artery bypass grafting; hs-cTnI -- high-sensitivity cardiac troponin I (hs-cTnI); NT-proBNP -- N-terminal pro-B-type natriuretic peptide; eGFR -- estimated glomerular filtration rate; NYHA -- New York Heart Association;

P\<0.05 versus the survival group

###### 

Medications used on admission to hospital admission and during hospitalization in the survival group and the mortality group of patients with heart failure with reduced ejection fraction (HFrEF) due to ischemic heart disease (IHD).

  Medications                       Survival group (n=142)   Mortality group (n=82)
  --------------------------------- ------------------------ ------------------------------------------------------------------
  **On hospital admission:**                                 
   Antiplatelet, n (%)              130 (91.5)               76 (92.7)
   Statins, n (%)                   89 (62.7)                51 (62.2)
   ACEi/ARB, n (%)                  106 (74.6)               60 (73.2)
   Spironolactone, n (%)            47 (33.1)                28 (34.1)
   Beta-blocker, n (%)              95 (66.9)                45 (54.9)[\*](#tfn4-medscimonit-26-e922129){ref-type="table-fn"}
   Oral hypoglycemic drugs, n (%)   32 (22.5)                20 (24.4)
   Insulin, n (%)                   18 (12.7)                17 (20.7)
   Oral diuretic, n (%)             134 (94.4)               77 (93.9)
   Calcium channel blocker, n (%)   20 (14.1)                13 (15.9)
   Digoxin, n (%)                   43 (30.3)                36 (43.9)[\*](#tfn4-medscimonit-26-e922129){ref-type="table-fn"}
   Potassium supplement, n (%)      59 (41.5)                35 (42.7)
  **In-hospital:**                                           
   Antiplatelet, n (%)              130 (91.5)               76 (92.7)
   Statins, n (%)                   89 (62.7)                51 (62.2)
   ACEi/ARB, n (%)                  108 (76.1)               59 (72)
   Spironolactone, n (%)            47 (33.1)                28 (34.1)
   Beta-blocker, n (%)              52 (36.6)                28 (34.1)
   Oral hypoglycemic drugs, n (%)   29 (20.4)                18 (22)
   Insulin, n (%)                   20 (14.1)                16 (19.5)
   Oral diuretic, n (%)             68 (47.9)                38 (46.3)
   Intravenous furosemide, n (%)    142 (100)                82 (100)
   Calcium channel blocker, n (%)   10 (7)                   6 (4.2)
   Digoxin, n (%)                   26 (18.3)                16 (19.5)
   Potassium supplement, n (%)      97 (68.3)                58 (70.7)
   Intravenous inotrope, n (%)      108 (76.1)               70 (85.4)[\*](#tfn4-medscimonit-26-e922129){ref-type="table-fn"}
   Intravenous vasodilator, n (%)   87 (61.3)                58 (70.7)[\*](#tfn4-medscimonit-26-e922129){ref-type="table-fn"}

ACEi/ARB -- angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; Intravenous inotrope, dopamine or dobutamine; Intravenous vasodilator, nitroprusside or nitroglycerine;

P\<0.05 versus the survival group

###### 

Comparisons of the two-dimensional transthoracic echocardiography (2D-TTE) and three-dimensional transthoracic echocardiography (3D-TTE) parameters in the survival group and the mortality group of patients with heart failure with reduced ejection fraction (HFrEF) due to ischemic heart disease (IHD).

  Parameters               Survival group (n=142)   Mortality group (n=82)
  ------------------------ ------------------------ ------------------------------------------------------------------
  2D-TTE                                            
   LVEF (%)                34±5                     32±7
   LVEDV (ml)              85.4±18.5                89.7±20.5[\*](#tfn6-medscimonit-26-e922129){ref-type="table-fn"}
   LVEDV index (ml/m^2^)   42.2±9.1                 45.3±10.3[\*](#tfn6-medscimonit-26-e922129){ref-type="table-fn"}
   LVESV (ml)              42.6±11.7                44.8±12.9
   LVESV index (ml/m^2^)   21.2±5.8                 22.4±6.1
  3D-TTE                                            
   LVEF (%)                32±7                     29±8[\*](#tfn6-medscimonit-26-e922129){ref-type="table-fn"}
   LVEDV (ml)              91.7±20.8                96.5±22.4[\*](#tfn6-medscimonit-26-e922129){ref-type="table-fn"}
   LVEDV index (ml/m^2^)   45.8±10.4                49.1±12.6[\*](#tfn6-medscimonit-26-e922129){ref-type="table-fn"}
   LVESV (ml)              45.9±13.3                49.6±14.0[\*](#tfn6-medscimonit-26-e922129){ref-type="table-fn"}
   LVESV index (ml/m^2^)   23.6±6.3                 26.0±7.9[\*](#tfn6-medscimonit-26-e922129){ref-type="table-fn"}

LVEF -- left ventricular ejection fraction; LVEDV -- left ventricular end diastolic volume; LVESV -- left ventricular end systolic volume;

P\<0.05 versus the survival group

###### 

Factors associated with all-cause mortality during hospitalizationusing two-dimensional transthoracic echocardiography (2D-TTE) and three-dimensional transthoracic echocardiography (3D-TTE).

  Factors                                  Univariate regression   Multivariate regression                       
  ---------------------------------------- ----------------------- ------------------------- ------------------- --------------
  **2D-TTE**                               **OR (95% CI)**         **P-value**               **OR (95% CI)**     **P-value**
  Age                                      1.28 (1.13--1.97)       0.004                     1.14 (1.05--1.39)   0.031
  Female *vs.* Male                        1.09 (1.04--1.33)       0.026                     1.02 (0.96--1.17)   0.182
  Systolic blood pressure                  1.13 (1.07--1.42)       0.011                     1.05 (0.98--1.20)   0.075
  Heart rate                               1.03 (0.97--1.13)       0.184                     NA                  
  Smoking status (yes *vs.* no)            1.16 (1.02--1.28)       0.033                     1.06 (0.94--1.17)   0.069
  Obesity (yes *vs.* no)                   1.05 (0.98--1.07)       0.340                     NA                  
  Hypertension (yes *vs.* no)              1.18 (1.09--1.39)       0.009                     1.08 (0.99--1.25)   0.060
  Diabetes mellitus (yes *vs.* no)         1.37 (1.19--1.67)       0.001                     1.25 (1.10--1.44)   0.007
  Dyslipidemia (yes *vs.* no)              1.01 (0.92--1.08)       0.255                     NA                  
  Prior MI (yes *vs.* no)                  1.20 (1.11--1.32)       0.018                     1.09 (1.02--1.21)   0.043
  Prior PCI (yes *vs.* no)                 1.05 (0.97--1.18)       0.075                     1.01 (0.92--1.08)   0.335
  Prior CABG (yes *vs.* no)                1.09 (1.01--1.22)       0.017                     1.02 (0.96--1.13)   0.086
  eGFR                                     0.92 (0.85--0.97)       0.031                     0.96 (0.90--1.02)   0.067
  Intravenous inotrope (yes *vs.* no)      1.24 (1.12--1.50)       0.006                     1.19 (1.08--1.37)   0.027
  Intravenous vasodilator (yes *vs.* no)   1.08 (0.96--1.20)       0.093                     1.04 (0.90--1.07)   0.155
  hs-cTNI                                  1.16 (1.08--1.25)       0.004                     1.09 (0.99--1.20)   0.052
  NT-proBNP                                1.39 (1.27--1.87)       \<0.001                   1.28 (1.18--1.45)   0.005
  LVEF                                     0.92 (0.86--0.97)       0.029                     0.94 (0.91--0.98)   0.043
  LVEDV index                              1.17 (1.08--1.28)       0.035                     1.05 (0.99--1.18)   0.061
  LVESV index                              1.10 (0.99--1.16)       0.051                     1.02 (0.95--1.10)   0.136
  **3D-TTE**                               **OR (95% CI)**         **P--value**              **OR (95% CI)**     **P--value**
  Age                                      1.25 (1.11--1.82)       0.008                     1.10 (1.03--1.31)   0.038
  Female *vs.* Male                        1.07 (1.01--1.26)       0.041                     1.01 (0.92--1.10)   0.204
  Systolic blood pressure                  1.10 (1.02--1.28)       0.036                     1.02 (0.93--1.11)   0.163
  Heart rate                               1.01 (0.95--1.09)       0.202                     NA                  
  Smoking status (yes *vs.* no)            1.12 (1.00--1.20)       0.051                     1.03 (0.90--1.07)   0.084
  Obesity (yes *vs.* no)                   1.02 (0.92--1.06)       0.450                     NA                  
  Hypertension (yes *vs.* no)              1.15 (1.04--1.25)       0.017                     1.04 (0.96--1.17)   0.069
  Diabetes mellitus (yes *vs.* no)         1.30 (1.15--1.57)       0.006                     1.17 (1.08--1.34)   0.025
  Dyslipidemia (yes *vs.* no)              1.01 (0.94--1.06)       0.532                     NA                  
  Prior MI (yes *vs.* no)                  1.18 (1.10--1.30)       0.026                     1.05 (1.00--1.18)   0.051
  Prior PCI (yes *vs.* no)                 1.02 (0.94--1.15)       0.090                     1.00 (0.90--1.07)   0.208
  Prior CABG (yes *vs.* no)                1.06 (1.01--1.16)       0.047                     1.01 (0.93--1.08)   0.097
  eGFR                                     0.93 (0.86--0.98)       0.032                     0.97 (0.91--1.05)   0.084
  Intravenous inotrope (yes *vs.* no)      1.20 (1.10--1.43)       0.009                     1.12 (1.04--1.27)   0.036
  Intravenous vasodilator (yes *vs.* no)   1.05 (0.92--1.17)       0.098                     1.01 (0.90--1.05)   0.236
  hs-cTNI                                  1.14 (1.05--1.22)       0.006                     1.07 (0.95--1.14)   0.073
  NT-proBNP                                1.32 (1.20--1.68)       \<0.001                   1.21 (1.11--1.35)   0.008
  LVEF                                     0.88 (0.83--0.95)       0.021                     0.92 (0.87--0.98)   0.039
  LVEDV index                              1.20 (1.12--1.30)       0.015                     1.11 (1.03--1.21)   0.043
  LVESV index                              1.11 (0.98--1.22)       0.086                     1.04 (0.92--1.08)   0.078

OR -- odds ratio; CI -- confidence interval; MI -- myocardial infarction; PCI -- percutaneous coronary intervention; CABG -- coronary artery bypass grafting; eGFR -- estimated glomerular filtration rate; hs-cTNI -- high-sensitivity cardiac troponin I; NT-proBNP -- N-terminal pro-B-type natriuretic peptide; LVEF -- left ventricular ejection faction; LVEDV -- left ventricular end diastolic volume; LVESV -- left ventricular end systolic volume.

###### 

Comparisons of two-dimensional transthoracic echocardiography (2D-TTE) and three-dimensional transthoracic echocardiography (3D-TTE) parameters for the prediction of in-hospital all-cause mortality in patients with heart failure with reduced ejection fraction (HFrEF) due to ischemic heart disease (IHD).

  Model      Odds ratio (95% CI)   Concordance statistic (C-index) (95% CI)
  ---------- --------------------- ------------------------------------------
  2D-TTE                           
   Model 1   1.78 (1.49--2.34)     0.72 (0.68--0.76)
   Model 2   1.82 (1.53--2.45)     0.77 (0.72--0.80)
   Model 3   1.79 (1.50--2.36)     0.74 (0.69--0.77)
   Model 4   1.77 (1.48--2.32)     0.71 (0.66--0.75)
  3D-TTE                           
   Model 1   1.78 (1.49--2.34)     0.72 (0.68--0.76)
   Model 2   1.87 (1.60--2.59)     0.80 (0.73--0.85)
   Model 3   1.82 (1.54--2.44)     0.76 (0.71--0.80)
   Model 4   1.78 (1.47--2.30)     0.73 (0.67--0.75)

CI -- confidence interval; Model 1 -- age, diabetes mellitus, prior MI, intravenous inotrope use, NT-proBNP. Model 2 -- model 1 plus LVEF. Model 3 -- model 1 plus LVEDV index. Model 4 -- model plus LVESV index.
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